Vascular Biogenics Ltd expected to post a loss of 13  cents a share - Earnings Preview

Notable Labs

07/05/2021 15:44

* Vascular Biogenics Ltd  VBLT.OQ   VBLT.O  is expected to show
a fall in quarterly revenue when it reports results on May 11 .
* The Modiin, Israel-based company is expected to report   a
45.4% decrease in revenue to $200 thousand from $366 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Vascular Biogenics Ltd
is for a loss of 13 cents per share. For the same quarter last
year, the company reported a loss of 15 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Vascular
Biogenics Ltd is $5​, about 59.4% above​ its last closing price
of $2.03. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Dec. 31 2020              -0.14      -0.15     Missed  -7.1
 Sep. 30 2020  -0.14       -0.13      -0.12     Beat    10.2
 Jun. 30 2020  -0.14       -0.14      -0.14     Met     -1.4​
 Mar. 31 2020  -0.17       -0.17      -0.15     Beat    9.4
 Dec.          -0.13​      -0.13      -0.16     Missed  -19.4​
 31​ 2019​                                              
 Sep. 30 2019  -0.16       -0.14      -0.14     Met     1.8​
 Jun. 30 2019  -0.14       -0.13      -0.13     Met     3.7
 Mar. 31 2019  -0.11       -0.12      -0.12     Met     0
 This summary was machine generated May 7 at 14:44 GMT.  All
figures in US dollars unless otherwise stated